With a background in chemical engineering and biochemistry Christopher I. Halliday counsels clients on strategic intellectual property (IP) issues in pharmaceutical, biotechnology, chemical, medical devices, and food science areas. He prepares and prosecutes patent applications related to new chemical entities, pharmaceutical formulations, and biologics as well as implantable medical devices, chemical processes and catalysts. Clients turn to Christopher for IP litigation advice and to develop opinions involving infringement, validity, and freedom to operate.
Clients also request Christopher’s assistance in the course of mergers or acquisitions, and negotiating licenses, transfer agreements, and assignments.
Before joining Morgan Lewis, Christopher was employed by a Philadelphia-area IP boutique law firm as an associate. He has also worked at SmithKlineBeecham Pharmaceuticals (now GlaxoSmithKline), the New Hampshire Office of the Attorney General, and the New Hampshire Office of the Public Defender. Christopher has represented many indigent clients in the New Hampshire courts.
Before entering private practice, Christopher worked for corporate, nonprofit, and government organizations.
Represented Merck in its up to $5.76 billion strategic collaboration with Eisai Co. Ltd. for the worldwide co-development and co-commercialization of Eisai's Lenvima (lenvatinib mesylate)
Represented SQZ Biotechnologies in its $1.37B-plus deal with Roche for a new approach to immuno-oncology where Roche is putting up $125 million for an upfront and near-term milestones in a collaboration deal embedded with $1 billion in development milestones and another $250 million for each new therapy that manages to receive approval. Roche and SQZ will jointly develop anticancer cell therapies that trigger antitumor responses with cell therapies that can target antigens that are beyond the reach of other cell-based adoptive immunity strategies
Represented Eli Lilly in its agreement with NextCure, Inc. for the discovery and development of immuno-oncology therapies to discover novel cancer targets utilizing NextCure's proprietary FIND-IO™ platform. Under the terms of the agreement, Lilly and NextCure will each receive options to exclusively license antibodies resulting from the collaboration
Represented Nevakar Inc. in its $50 million product financing agreement with an affiliate of NovaQuest Capital Management, for the continued development of five differentiated, sterile injectable products
Represented Regeneron in its up to $1 billion agreement with Alnylam Pharmaceuticals for the development and commercialization of new RNA interference therapeutics for diseases in the eye, central nervous system and liver. As part of the transaction, Regeneron made a $400 million investment in Alnylam equity
Represented Acerta Pharma B.V. in implementation of IP program and in its acquisition by AstraZeneca
Established and implemented intellectual property programs for many small, midsize, and multinational companies in the life sciences, technology and financial services sector
Represented OncoEthix SA in implementation of IP program and in its acquisition by Merck
Represented Foresight Biotherapeutics, Inc. in implementation of an IP program, and acquisition of Foresight by Shire
Represented Tabula Rasa HealthCare, Inc. in connection with its $60 million initial public offering
Represented medical device company in litigation in the Western District of Washington resulting in favorable settlement
Developed and attended Proof of Concept program at the University of Delaware
Franklin Pierce Law Center, 1999, J.D.
Pennsylvania State University, 1996, B.S.
Temple University, Beasley School of Law, 2002, LL.M.
U.S. Patent and Trademark Office
Awards and Affiliations
Member, Engineering Advisory Committee Board for Penn State University, 2017-Current
Member, Practice Group of the Year, Intellectual Property, Law360 (2019)
Member, Litigation Department of the Year–Intellectual Property, The American Lawyer (2019)